| Malignant Ovarian Clear Cell Tumor studied in …STUDIED_INderived10 of 66show all (up to 200) |
|---|
| → studied in | NCT05920798Phase 1/Phase 2 · active not recruiting Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped CURATED_BROADER · 66 trials mapped (19 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07718854Phase 2 · recruiting Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer · condition mapped CURATED_BROADER · 66 trials mapped (19 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04575935Phase 3 · recruiting Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial · condition mapped ONTOLOGY_EXACT · 66 trials mapped (19 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02101775Phase 2 · active not recruiting Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 66 trials mapped (19 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05950464Phase 1 · recruiting Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer · condition mapped CURATED_BROADER · 66 trials mapped (19 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02142803Phase 1 · active not recruiting TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 66 trials mapped (19 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02839707Phase 2/Phase 3 · active not recruiting Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped CURATED_BROADER · 66 trials mapped (19 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02068794Phase 1/Phase 2 · active not recruiting MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 66 trials mapped (19 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05231122Phase 2 · recruiting Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 66 trials mapped (19 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05226507Phase 1 · terminated A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 66 trials mapped (19 active) | — | — | Ovarian Clear Cell Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |